News

IGI with Cancer Health Solutions Resources (CHS) will develop a Novasome technology based over the counter sunscreen product containing CHS’s proprietary ingredients that may enhance the antioxidant effect

Mr Krayacich will be responsible for leading the company’s drug and business development for ganaxolone, an adult and pediatric epilepsy candidate in Phase II, and chelerythrine, a preclinical

Gioacchino Chirico, president and CEO of Immucor, said: “We are pleased to have completed this acquisition, which we believe will enable us to provide innovative molecular diagnostic solutions

In exchange for all of the company’s operating assets, Clinical Data paid $11 million in cash, and entered into a $22 million, five-year promissory note and a separate

The last of around 4,500 patients was recruited in the final week of June 2008, and the three-year study will be conducted in North and South America, Europe

Each study, conducted under an FDA special protocol assessment, met all primary endpoints and showed statistically significant results. The pivotal, Phase III placebo-controlled studies investigating the efficacy and

The Phase Ia single-center clinical trial evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in

The patent covers, amongst others, compositions where the active ingredient is selected from mesalazine, budesonide, metformin, octylonium bromide, gabapentin, carbidopa, nimesulide, propionylcarnitine, isosorbide mono- and dinitrate, naproxen, ibuprofen,

Under the agreement Aquapharm will use its proprietary assays to screen its library of marine microbes for the discovery and generation of novel cosmetic ingredients for skin and